Search Within

Oscar Boutros Lahoud

Formats
  1. Meeting Abstract (88)
  2. Journal Article (37)
  3. Research Letter (6)
  4. Correspondence (2)
  5. Review (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (130)
  4. Survivorship Research (126)
  5. Bone Marrow Transplant (124)
  6. CTCR Scholars (113)

More Groups

People
  1. Sergio Giralt (108)
  2. Gunjan Shah (106)
  3. Heather Landau (103)
  4. Michael Scordo (99)
  5. David Chung (93)
  6. Hani Hassoun (89)

More People

Years
  1. 2025 (2)
  2. 2024 (12)
  3. 2023 (42)
  4. 2022 (28)
  5. 2021 (10)
  6. 2020 (18)

More Years

Publications
  1. Blood (47)
  2. Clinical Lymphoma, Myeloma and Leukemia (26)
  3. Biology of Blood and Marrow Transplantation (10)
  4. Blood Advances (9)
  5. Journal of Clinical Oncology (8)
  6. Leukemia and Lymphoma (6)

More Publications

Publishers
  1. American Society of Hematology (56)
  2. Elsevier Inc. (41)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. Taylor & Francis Group (6)
  6. John Wiley & Sons (3)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis
    Journal Article

    Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents
    Meeting Abstract

    Roeker, L. E.; Brown, J. R.; Dreger, P.; Lahoud, O. B.; Eyre, T. A.; Brander, D. M.; Skarbnik, A.; Coombs, C. C.; Kim, H. T.; Manchini, S. T.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H. J.; Rosenbaum, C. A.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Outpatient BEAM using daily etoposide and cytarabine with autologous hematopoietic stem cell transplantation for lymphoma is feasible and decreases inpatient length of stay
    Meeting Abstract

    Cazeau, N.; Cavalier, K.; Bhatt, V.; McElrath, C.; Lestrange, N.; Lachaud-Richard, M.; Inumerables, F.; Andrejko, M.; Batalha, J.; Cohen, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H.; Rosenbaum, C.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save